AtaiBeckley joins Russell 2000, 3000 indexes with $12.2 trillion in assets

AtaiBeckley Inc. will join the Russell 2000 Index and the broad-market Russell 3000 Index on June 29, expanding the clinical-stage biotech company's visibility among institutional investors who benchmark roughly $12.2 trillion against the Russell U.S. indexes.

"Joining the Russell Indexes — which collectively benchmark approximately $12.2 trillion in assets — represents another meaningful milestone for AtaiBeckley as we continue to expand our presence across the U.S. equity benchmark landscape, and increase visibility with a broad base of institutional investors," said Srinivas Rao, co-founder and chief executive officer of AtaiBeckley. "With our Phase 3 study of BPL-003 advancing, this development comes at an important time for the company and reflects the maturity and strength of both our team and our late-stage mental health pipeline."

The addition, effective at the open of U.S. markets on June 29 as part of the 2026 Russell indexes reconstitution, follows AtaiBeckley's inclusion in the S&P Total Market Index, S&P Completion Index and CRSP U.S. benchmark indexes in March. The Russell 2000 measures the performance of about 2,000 small-cap U.S. equities, while the Russell 3000 covers approximately 3,000 stocks representing roughly 98 percent of investable U.S. equities by market capitalization. FTSE Russell determines membership primarily by objective, market-capitalization rankings and style attributes.

AtaiBeckley is developing rapid-acting mental health treatments, with its lead candidate BPL-003 — a mebufotenin benzoate nasal spray for treatment-resistant depression — granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration and now in Phase 3 development. Two other candidates, VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCl) for social anxiety disorder, are in Phase 2 trials. The company is also advancing a discovery program for non-hallucinogenic 5-HT2AR agonists targeting opioid use disorder and TRD.

The index inclusion comes at a critical time for AtaiBeckley as it advances its late-stage pipeline. With roughly $12.2 trillion in assets benchmarked to the Russell indexes, passive fund flows from index-tracking strategies are expected to drive incremental buying of ATAI shares. The company's addition to four major U.S. benchmark families — Russell, S&P and CRSP — within a single quarter shows growing institutional recognition of its pipeline maturity. AtaiBeckley trades on the Nasdaq under the ticker ATAI.

This article is for informational purposes only and does not constitute investment advice.